Introduction Transmission-blocking vaccines (TBV) prevent community spread of malaria by
targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in …

Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …

Malaria transmission-blocking vaccines (TBVs) reduce disease transmission by breaking the
continuous cycle of infection between the human host and the mosquito vector. Domain 1 …

Abstract Proteins Pfs230 and Pfs48/45 are Plasmodium falciparum transmission-blocking
(TB) vaccine candidates that form a membrane-bound protein complex on gametes. The …

Malaria is still the most widespread parasitic disease and causes the most infections
globally. Owing to improvements in sanitary conditions and various intervention measures …

Malaria elimination requires tools that interrupt parasite transmission. Here, we characterize
B cell receptor responses among Malian adults vaccinated against the first domain of the …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

A vaccine targeting multiple stages of the Plasmodium falciparum parasite life cycle is
desirable. The sporozoite surface Circumsporozoite Protein (CSP) is the target of leading …

Malaria transmission-blocking vaccines candidates based on Pfs25 and Pfs230 have
advanced to clinical studies. Exoprotein A (EPA) conjugate of Pfs25 in Alhydrogel® …

Abstract The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are leading candidates
for a malaria transmission-blocking vaccine (TBV). Previously, we showed that a Pfs230 …